{"entity":{"type":"insider","cik":"0001777421","url":"/insider/0001777421","json_url":"/insider/0001777421.json","name":"Sepp-Lorenzino Laura","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":24,"n_filings":7,"first":"2021-08-06","last":"2025-01-07","span_basis":"filed_date"},"name_variants":[{"name":"Sepp-Lorenzino Laura","source":"filing","n_filings":7,"first_seen":"2021-08-06","last_seen":"2025-01-07"}],"transactions":[{"id":5156267,"accession":"0000950170-25-003002","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-003002","line_url":"/filing/0000950170-25-003002#line-1","is_derivative":false,"issuer_cik":"0001652130","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001652130","owner_cik":"0001777421","owner_name":"Sepp-Lorenzino Laura","owner_display_name":"Sepp-Lorenzino Laura","owner_url":"/insider/0001777421","role":"Officer (EVP, Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8966.0,"shares_display":"8,966","price_per_share":12.18,"price_display":"12.18","price_state":"stated","total_value":109205.88,"total_display":"109,205.88","total_whole":"109,206","shares_owned_after":77388.0,"shares_owned_after_display":"77,388","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-03","filed_date":"2025-01-07","scope":"insider"},{"id":2633866,"accession":"0000950170-24-003632","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-003632","line_url":"/filing/0000950170-24-003632","is_derivative":false,"issuer_cik":"0001652130","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001652130","owner_cik":"0001777421","owner_name":"Sepp-Lorenzino Laura","owner_display_name":"Sepp-Lorenzino Laura","owner_url":"/insider/0001777421","role":"Officer (EVP, Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2275.0,"shares_display":"2,275","price_per_share":28.871094505494504,"price_display":"28.87","price_state":"stated","total_value":65681.74,"total_display":"65,681.74","total_whole":"65,682","shares_owned_after":44594.0,"shares_owned_after_display":"44,594","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-08","filed_date":"2024-01-10","scope":"insider","n_lines":2},{"id":2673020,"accession":"0000950170-24-002514","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-002514","line_url":"/filing/0000950170-24-002514#line-1","is_derivative":false,"issuer_cik":"0001652130","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001652130","owner_cik":"0001777421","owner_name":"Sepp-Lorenzino Laura","owner_display_name":"Sepp-Lorenzino Laura","owner_url":"/insider/0001777421","role":"Officer (EVP, Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5532.0,"shares_display":"5,532","price_per_share":29.46,"price_display":"29.46","price_state":"stated","total_value":162972.72,"total_display":"162,972.72","total_whole":"162,973","shares_owned_after":46202.0,"shares_owned_after_display":"46,202","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-03","filed_date":"2024-01-05","scope":"insider"},{"id":8542562,"accession":"0001209191-23-002433","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-23-002433","line_url":"/filing/0001209191-23-002433","is_derivative":false,"issuer_cik":"0001652130","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001652130","owner_cik":"0001777421","owner_name":"Sepp-Lorenzino Laura","owner_display_name":"Sepp-Lorenzino Laura","owner_url":"/insider/0001777421","role":"Officer (EVP, Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2330.0,"shares_display":"2,330","price_per_share":38.48022317596566,"price_display":"38.48","price_state":"stated","total_value":89658.92,"total_display":"89,658.92","total_whole":"89,659","shares_owned_after":18318.0,"shares_owned_after_display":"18,318","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-05","filed_date":"2023-01-06","scope":"insider","n_lines":2},{"id":8542555,"accession":"0001209191-23-002433","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-002433","line_url":"/filing/0001209191-23-002433#line-1","is_derivative":false,"issuer_cik":"0001652130","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001652130","owner_cik":"0001777421","owner_name":"Sepp-Lorenzino Laura","owner_display_name":"Sepp-Lorenzino Laura","owner_url":"/insider/0001777421","role":"Officer (EVP, Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2508.0,"shares_display":"2,508","price_per_share":37.21,"price_display":"37.21","price_state":"stated","total_value":93322.68,"total_display":"93,322.68","total_whole":"93,323","shares_owned_after":19959.0,"shares_owned_after_display":"19,959","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-04","filed_date":"2023-01-06","scope":"insider"},{"id":6947989,"accession":"0001209191-22-015976","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-015976","line_url":"/filing/0001209191-22-015976#line-2","is_derivative":false,"issuer_cik":"0001652130","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001652130","owner_cik":"0001777421","owner_name":"Sepp-Lorenzino Laura","owner_display_name":"Sepp-Lorenzino Laura","owner_url":"/insider/0001777421","role":"Officer (EVP, Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1148.0,"shares_display":"1,148","price_per_share":112.25,"price_display":"112.25","price_state":"stated","total_value":128863.0,"total_display":"128,863.00","total_whole":"128,863","shares_owned_after":4815.0,"shares_owned_after_display":"4,815","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-01","filed_date":"2022-03-03","scope":"insider"},{"id":4486168,"accession":"0001209191-21-054321","txn_seq":11,"anchor":"line-11","filing_url":"/filing/0001209191-21-054321","line_url":"/filing/0001209191-21-054321","is_derivative":false,"issuer_cik":"0001652130","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001652130","owner_cik":"0001777421","owner_name":"Sepp-Lorenzino Laura","owner_display_name":"Sepp-Lorenzino Laura","owner_url":"/insider/0001777421","role":"Officer (EVP, Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":97000.0,"shares_display":"97,000","price_per_share":154.82530340206185,"price_display":"154.83","price_state":"stated","total_value":15018054.43,"total_display":"15,018,054.43","total_whole":"15,018,054","shares_owned_after":34238.0,"shares_owned_after_display":"34,238","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-08-30","filed_date":"2021-09-01","scope":"insider","n_lines":9},{"id":5477654,"accession":"0001209191-21-050228","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001209191-21-050228","line_url":"/filing/0001209191-21-050228","is_derivative":false,"issuer_cik":"0001652130","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001652130","owner_cik":"0001777421","owner_name":"Sepp-Lorenzino Laura","owner_display_name":"Sepp-Lorenzino Laura","owner_url":"/insider/0001777421","role":"Officer (EVP, Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":26000.0,"shares_display":"26,000","price_per_share":138.2444973076923,"price_display":"138.24","price_state":"stated","total_value":3594356.93,"total_display":"3,594,356.93","total_whole":"3,594,357","shares_owned_after":20106.0,"shares_owned_after_display":"20,106","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-08-04","filed_date":"2021-08-06","scope":"insider","n_lines":7}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":24,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":24,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":24},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001652130","name":"Intellia Therapeutics, Inc.","url":"/issuer/0001652130","role":"Officer (EVP, Chief Scientific Officer)","n_filings":7,"first_seen":"2021-08-06","last_seen":"2025-01-07"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001777421","retrieved_at":"2026-08-25T06:51:28+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}